Finding the best prices at pharmacies near you...

Hodgkin's Disease

Hodgkin's Disease

Hodgkin's disease, also known as Hodgkin's lymphoma, is an immune disease characterized by abnormal growth of cells in the lymphatic system. This form of cancer is most common in young adults between 15 and 35 years of age, or in adults over the age of 50. 

Lymphoma occurs when cells in the lymph nodes start to produce malignant cells that can attack other tissues in the body. Hodgkin's disease is the rarer of the two varieties of lymphatic cancer, the other being non-Hodgkin's lymphoma. There are four kinds of Hodgkin's disease: chronic lymphocytic leukemia; cutaneous B-cell lymphoma; cutaneous T-cell lymphoma; and lymphoma. 

Among the common symptoms of Hodgkin's disease are swelling of the lymph nodes in the armpit, groin or neck; fever; night sweats, unexplained weight loss; fatigue; itching; and a heightened sensitivity to alcohol. Risk factors for the condition include age, a family history of the disease, being male, and a history of illnesses caused by the Epstein-Barr virus. 

Treatment of Hodgkin's disease depends on the stage of cancer, but options include chemotherapy, radiation therapy, bone marrow transplants, and drug therapy using medication. Drug classes sometimes used to treat Hodgkin's disease are nitrosoureas, nitrogen mustard analogs, methylhydrazines, other cytotoxic antibiotics, other topical antineoplastics, antineoplastic monoclonal antibodies, and vinca alkaloids and analogs.

Drugs Used To Treat Hodgkin's Disease:



Drugs related to Hodgkin's Disease:

Blog Posts Related to Hodgkin's Disease:


The US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) as a treatment for certain adult patients with classical Hodgkin lymphoma (cHL). Under the latest approval, the Seattle Genetics drug is indicated for use in combination with chemotherapy as a treatment for...

Read More... Mar 20, 2018

The US Food and Drug Administration (FDA) has issued a statement clarifying its position on Keytruda (pembrolizumab) after scientists monitoring studies of the drug found an excess of deaths among patients given the drug in combination with certain other medicines.  Currently, Keytruda is...

Read More... Sep 10, 2017

The US Food & Drug Administration's (FDA) decision to approve a medication to treat patients whose cancer has a specific genetic feature, or biomarker, has been hailed as an "important first" in the fight against the disease. Keytruda (pembrolizumab) is a monoclonal antibody already in use to...

Read More... May 24, 2017